Funding for this research was provided by:
Japan Agency for Medical Research and Development
Received: 15 April 2019
Accepted: 21 August 2019
First Online: 3 October 2019
Ethics approval and consent to participate
: Our study with human iPS cells has been approved by the Ethics Committee about human ES, human iPS, and human tissue stem cells in Keio University School of Medicine (reference number: 2018-04).
: Not applicable
: Shin Hatou received fees from Cellusion, Inc. and is holding stocks in Cellusion, Inc. Shigeto Shimmura received funding from Cellusion, Inc. and is holding stocks in Cellusion, Inc.